Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Equity Ratio (2017 - 2025)

Sutro Biopharma's Equity Ratio history spans 9 years, with the latest figure at 0.42 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 269.1% year-over-year to 0.42; the TTM value through Sep 2025 reached 0.42, down 269.1%, while the annual FY2024 figure was 0.12, 63.77% down from the prior year.
  • Equity Ratio for Q3 2025 was 0.42 at Sutro Biopharma, down from 0.12 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.86 in Q1 2021 and bottomed at 0.42 in Q3 2025.
  • The 5-year median for Equity Ratio is 0.33 (2023), against an average of 0.39.
  • The largest annual shift saw Equity Ratio skyrocketed 60.69% in 2021 before it tumbled 269.1% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.74 in 2021, then decreased by 27.9% to 0.53 in 2022, then plummeted by 40.4% to 0.32 in 2023, then tumbled by 63.77% to 0.12 in 2024, then tumbled by 461.36% to 0.42 in 2025.
  • Per Business Quant, the three most recent readings for STRO's Equity Ratio are 0.42 (Q3 2025), 0.12 (Q2 2025), and 0.08 (Q1 2025).